Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders

Raffaella Cusmai, Alberto Verrotti, Romina Moavero, Paolo Curatolo, Domenica Battaglia, Sara Matricardi, Alberto Spalice, Federico Vigevano, Dario Pruna, Pasquale Parisi, Alfredo D'Aniello, Giancarlo Di Gennaro, Giangennaro Coppola

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and tolerability of add-on rufinamide in children with refractory epilepsy symptomatic of neuronal migration disorders. Materials and methods: We recruited 69 patients in a prospective, open-label, add-on treatment study from six Italian and one German centers for pediatric and adolescent epilepsy care according to the following criteria: age 3 or above; focal or generalized seizures refractory to at least three previous antiepileptic drugs (AEDs), alone or in combination, secondary to neuronal migration disorders; two or more seizures per month in the last 6 months; use of another AED, but no more than three, at baseline. Informed consent from parents and/or caregivers was obtained at the time of enrollment. Results: We enrolled 69 patients with a mean age of 15 years (range 3-43). Forty-three patients (62%) had a 50-99% seizure reduction, and two (3%) became seizure-free. Seizure frequency was unchanged in 18 (26%) and worsened in 6 (8.7%). Twenty-nine patients (42%) reported adverse side effects, whilst taking rufinamide. Irritability was the most common side effect (11 patients), followed by decreased appetite (10), mood shift (6), vomiting (5), drowsiness (4), and decreased attention (2). Blood levels of concomitant anticonvulsive drugs were transiently abnormal in 5 patients. Conclusion: In our population of severely refractory epilepsy due to neuronal migration disorders, rufinamide appeared to be effective and generally well tolerated.

Original languageEnglish
Pages (from-to)542-546
Number of pages5
JournalEpilepsy Research
Volume108
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Group II Malformations of Cortical Development
Epilepsy
Seizures
Anticonvulsants
Therapeutics
Sleep Stages
Appetite
Informed Consent
Caregivers
Vomiting
rufinamide
Parents
Pediatrics

Keywords

  • Neuronal migration disorders
  • Partial epilepsy
  • Refractory seizures
  • Rufinamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. / Cusmai, Raffaella; Verrotti, Alberto; Moavero, Romina; Curatolo, Paolo; Battaglia, Domenica; Matricardi, Sara; Spalice, Alberto; Vigevano, Federico; Pruna, Dario; Parisi, Pasquale; D'Aniello, Alfredo; Di Gennaro, Giancarlo; Coppola, Giangennaro.

In: Epilepsy Research, Vol. 108, No. 3, 2014, p. 542-546.

Research output: Contribution to journalArticle

Cusmai, R, Verrotti, A, Moavero, R, Curatolo, P, Battaglia, D, Matricardi, S, Spalice, A, Vigevano, F, Pruna, D, Parisi, P, D'Aniello, A, Di Gennaro, G & Coppola, G 2014, 'Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders', Epilepsy Research, vol. 108, no. 3, pp. 542-546. https://doi.org/10.1016/j.eplepsyres.2014.01.013
Cusmai, Raffaella ; Verrotti, Alberto ; Moavero, Romina ; Curatolo, Paolo ; Battaglia, Domenica ; Matricardi, Sara ; Spalice, Alberto ; Vigevano, Federico ; Pruna, Dario ; Parisi, Pasquale ; D'Aniello, Alfredo ; Di Gennaro, Giancarlo ; Coppola, Giangennaro. / Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. In: Epilepsy Research. 2014 ; Vol. 108, No. 3. pp. 542-546.
@article{67120363a60b45a9b09093bf82ac6ea5,
title = "Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders",
abstract = "Objective: To evaluate the efficacy and tolerability of add-on rufinamide in children with refractory epilepsy symptomatic of neuronal migration disorders. Materials and methods: We recruited 69 patients in a prospective, open-label, add-on treatment study from six Italian and one German centers for pediatric and adolescent epilepsy care according to the following criteria: age 3 or above; focal or generalized seizures refractory to at least three previous antiepileptic drugs (AEDs), alone or in combination, secondary to neuronal migration disorders; two or more seizures per month in the last 6 months; use of another AED, but no more than three, at baseline. Informed consent from parents and/or caregivers was obtained at the time of enrollment. Results: We enrolled 69 patients with a mean age of 15 years (range 3-43). Forty-three patients (62{\%}) had a 50-99{\%} seizure reduction, and two (3{\%}) became seizure-free. Seizure frequency was unchanged in 18 (26{\%}) and worsened in 6 (8.7{\%}). Twenty-nine patients (42{\%}) reported adverse side effects, whilst taking rufinamide. Irritability was the most common side effect (11 patients), followed by decreased appetite (10), mood shift (6), vomiting (5), drowsiness (4), and decreased attention (2). Blood levels of concomitant anticonvulsive drugs were transiently abnormal in 5 patients. Conclusion: In our population of severely refractory epilepsy due to neuronal migration disorders, rufinamide appeared to be effective and generally well tolerated.",
keywords = "Neuronal migration disorders, Partial epilepsy, Refractory seizures, Rufinamide",
author = "Raffaella Cusmai and Alberto Verrotti and Romina Moavero and Paolo Curatolo and Domenica Battaglia and Sara Matricardi and Alberto Spalice and Federico Vigevano and Dario Pruna and Pasquale Parisi and Alfredo D'Aniello and {Di Gennaro}, Giancarlo and Giangennaro Coppola",
year = "2014",
doi = "10.1016/j.eplepsyres.2014.01.013",
language = "English",
volume = "108",
pages = "542--546",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders

AU - Cusmai, Raffaella

AU - Verrotti, Alberto

AU - Moavero, Romina

AU - Curatolo, Paolo

AU - Battaglia, Domenica

AU - Matricardi, Sara

AU - Spalice, Alberto

AU - Vigevano, Federico

AU - Pruna, Dario

AU - Parisi, Pasquale

AU - D'Aniello, Alfredo

AU - Di Gennaro, Giancarlo

AU - Coppola, Giangennaro

PY - 2014

Y1 - 2014

N2 - Objective: To evaluate the efficacy and tolerability of add-on rufinamide in children with refractory epilepsy symptomatic of neuronal migration disorders. Materials and methods: We recruited 69 patients in a prospective, open-label, add-on treatment study from six Italian and one German centers for pediatric and adolescent epilepsy care according to the following criteria: age 3 or above; focal or generalized seizures refractory to at least three previous antiepileptic drugs (AEDs), alone or in combination, secondary to neuronal migration disorders; two or more seizures per month in the last 6 months; use of another AED, but no more than three, at baseline. Informed consent from parents and/or caregivers was obtained at the time of enrollment. Results: We enrolled 69 patients with a mean age of 15 years (range 3-43). Forty-three patients (62%) had a 50-99% seizure reduction, and two (3%) became seizure-free. Seizure frequency was unchanged in 18 (26%) and worsened in 6 (8.7%). Twenty-nine patients (42%) reported adverse side effects, whilst taking rufinamide. Irritability was the most common side effect (11 patients), followed by decreased appetite (10), mood shift (6), vomiting (5), drowsiness (4), and decreased attention (2). Blood levels of concomitant anticonvulsive drugs were transiently abnormal in 5 patients. Conclusion: In our population of severely refractory epilepsy due to neuronal migration disorders, rufinamide appeared to be effective and generally well tolerated.

AB - Objective: To evaluate the efficacy and tolerability of add-on rufinamide in children with refractory epilepsy symptomatic of neuronal migration disorders. Materials and methods: We recruited 69 patients in a prospective, open-label, add-on treatment study from six Italian and one German centers for pediatric and adolescent epilepsy care according to the following criteria: age 3 or above; focal or generalized seizures refractory to at least three previous antiepileptic drugs (AEDs), alone or in combination, secondary to neuronal migration disorders; two or more seizures per month in the last 6 months; use of another AED, but no more than three, at baseline. Informed consent from parents and/or caregivers was obtained at the time of enrollment. Results: We enrolled 69 patients with a mean age of 15 years (range 3-43). Forty-three patients (62%) had a 50-99% seizure reduction, and two (3%) became seizure-free. Seizure frequency was unchanged in 18 (26%) and worsened in 6 (8.7%). Twenty-nine patients (42%) reported adverse side effects, whilst taking rufinamide. Irritability was the most common side effect (11 patients), followed by decreased appetite (10), mood shift (6), vomiting (5), drowsiness (4), and decreased attention (2). Blood levels of concomitant anticonvulsive drugs were transiently abnormal in 5 patients. Conclusion: In our population of severely refractory epilepsy due to neuronal migration disorders, rufinamide appeared to be effective and generally well tolerated.

KW - Neuronal migration disorders

KW - Partial epilepsy

KW - Refractory seizures

KW - Rufinamide

UR - http://www.scopus.com/inward/record.url?scp=84895419009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895419009&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2014.01.013

DO - 10.1016/j.eplepsyres.2014.01.013

M3 - Article

VL - 108

SP - 542

EP - 546

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 3

ER -